Phase 2 trial results with the novel neurokinin-1 receptor antagonist casopitant in combination with ondansetron and dexamethasone for the prevention of chemotherapy-induced nausea and vomiting in cancer patients receiving moderately emetogenic chemotherapy

Cancer

Volumn 115, Issue 24, 2009, Pages 5807-5816

  Arpornwirat, Wichit ^a   Albert, Istvan ^b   Hansen, Vincent L ^c   Levin, Jeremey ^d   Bandekar, Rajesh R ^d   Grunberg, Steven M ^e  

^a NATIONAL CANCER INSTITUTE   (Thailand)

^b Mátrai Gyógyintézet ^*  (Hungary)

^c Utah Hematology Oncology   (United States)

^d GLAXOSMITHKLINE   (United States)

^e UNIVERSITY OF VERMONT   (United States)

Author keywords

Antiemetics; Antineoplastic combined chemotherapy protocols; Combination drug therapy; Nausea; Neoplasms; Neurokinin 1 receptors; Vomiting

Indexed keywords

CARBOPLATIN; CASOPITANT; CYCLOPHOSPHAMIDE; DEXAMETHASONE; DOCETAXEL; DOXORUBICIN; EPIRUBICIN; ETOPOSIDE; FLUOROURACIL; GEMCITABINE; IRINOTECAN; NEUROKININ 1 RECEPTOR ANTAGONIST; ONDANSETRON; OXALIPLATIN; PACLITAXEL; PLACEBO;

ADULT; AGED; ALOPECIA; ANEMIA; ANOREXIA; ARTICLE; BREAST CANCER; CANCER CHEMOTHERAPY; CANCER PATIENT; CHEMOTHERAPY INDUCED EMESIS; CLINICAL TRIAL; COLORECTAL CANCER; CONSTIPATION; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIARRHEA; DIZZINESS; DOSE RESPONSE; DOUBLE BLIND PROCEDURE; DRUG DOSE COMPARISON; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; DRUG WITHDRAWAL; EVENING DOSAGE; EXPLORATORY RESEARCH; FATIGUE; FEMALE; HUMAN; LUNG NON SMALL CELL CANCER; MAJOR CLINICAL STUDY; MALE; MORNING DOSAGE; MULTICENTER STUDY; NAUSEA; NEUTROPENIA; OUTCOME ASSESSMENT; OVARY CANCER; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; RETCHING; SINGLE BLIND PROCEDURE; STATISTICAL SIGNIFICANCE; TREATMENT RESPONSE; VISUAL ANALOG SCALE; VOMITING;

ADULT; AGED; AGED, 80 AND OVER; ANTIEMETICS; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; DEXAMETHASONE; DOUBLE-BLIND METHOD; DRUG ADMINISTRATION SCHEDULE; FEMALE; HUMANS; MALE; MIDDLE AGED; NAUSEA; ONDANSETRON; PIPERAZINES; PIPERIDINES; RECEPTORS, NEUROKININ-1; VOMITING;

EID: 73149083276     PISSN: 0008543X     EISSN: 10970142     Source Type: Journal    
DOI: 10.1002/cncr.24630     Document Type: Article

References (13)

1. Bloechl-Daum B, Deuson RR, Mavros P, Hansen M, Herrstedt J. Delayed nausea and vomiting continue to reduce patients' quality of life after highly and moderately emetogenic chemotherapy despite antiemetic treatment. J Clin Oncol. 2006;24:4472-4478.
2. Cohen L, de Moor CA, Eisenberg P, Ming EE, Hu H. Chemotherapy-induced nausea and vomiting: incidence and impact on patient quality of life at community oncology settings. Support Care Cancer. 2007;15:497-503.
3. Gagnon RC, King AG. Co-administration of ondansetron and casopitant mesylate, a novel NK-1 receptor antagonist, results in augmented anti-emetic activity in the ferret [abstract]. Proc Am Soc Clin Oncol. 2006;24:18S. Abstract 18608.
4. King A. Evaluation of the NK-1 receptor antagonist, GW679769, in cisplatin-induced acute and delayed emesis in the ferret [abstract]. Support Care Cancer. 2005;13:418. Abstract 04-030.
5. Chung F, Singla N, Singla S, Grenier A, Russo M. Casopitant for preventing postoperative vomiting in patients receiving opioids: pooled data analysis [abstract]. Paper presented at: 57th Annual Meeting of the American Society of Anesthesiologists; Madrid, Spain; October 13-17, 2006. Abstract A206.
6. Roila F, Rolski J, Ramlau R, Dediu M, Russo MW, Bandekar RR, Grunberg SM. Randomized, double-blind, dose-ranging trial of the oral neurokinin-1 receptor antagonist casopitant mesylate for the prevention of cisplatin-induced nausea and vomiting. Ann Oncol. In press.
7. GlaxoSmithKline. Data on file: GlaxoSmithKline Studies NKV10001 and NKV100787. Collegeville, Pa: GlaxoSmithKline; 2008.
8. Williams PL, Armitage P, Colton T. Trend tests for counts and proportions. Armitage P, Colton T, eds. Encyclopedia of Biostatistics. 6th ed. Chichester, United Kingdom: John Wiley & Sons; 1998:4573-4584.
9. Gralla RJ, Osoba D, Kris MJ, et al. Recommendations for the use of antiemetics: evidence-based, clinical practice guidelines. J Clin Oncol. 1999;17:2971-2994.
10. Roila F, Donati D, Tamberi S, et al. Delayed emesis: incidence, pattern, prognostic factors and optimal treatment. Support Care Cancer. 2002;10:88-95.
11. Multinational Association of Supportive Care in Cancer. Consensus Conference on Antiemetic Therapy, March 29-31, 2004, Perugia, Italy. Latest Update: April 2007. Available at: http://www.mascc.org/media/Resource-centers/ MASCC-Guidelines-Update.pdf Accessed August 8, 2007.
12. Kris MG, Hesketh PJ, Somerfield MR, et al. American Society of Clinical Oncology guideline for antiemetics in oncology: update 2006. J Clin Oncol. 2006;24:2932-2947.
13. Warr DG, Hesketh PJ, Gralla RJ, et al. Efficacy and tolerability of aprepitant for the prevention of chemotherapy-induced nausea and vomiting in patients with breast cancer after moderately emetogenic chemotherapy. J Clin Oncol. 2005;23:2822-2830.